Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more
Time Frame | ABBV | Sector | S&P500 |
---|---|---|---|
1-Week Return | 2.13% | -0.78% | -1.28% |
1-Month Return | 1.03% | 0.89% | 1.37% |
3-Month Return | 4.5% | 6.29% | 12.01% |
6-Month Return | 6.53% | 6.29% | 15.36% |
1-Year Return | 30% | 12.68% | 23.24% |
3-Year Return | 67.97% | 21.13% | 36.17% |
5-Year Return | 213.59% | 74.73% | 101.78% |
10-Year Return | 382.42% | 182.71% | 236.91% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | [{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}] |
Cost of Revenue | 7.44B | 15.39B | 17.45B | 17.41B | 8.78B | [{"date":"2019-12-31","value":42.64,"profit":true},{"date":"2020-12-31","value":88.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":50.33,"profit":true}] |
Gross Profit | 25.83B | 30.42B | 38.75B | 40.64B | 45.54B | [{"date":"2019-12-31","value":56.72,"profit":true},{"date":"2020-12-31","value":66.79,"profit":true},{"date":"2021-12-31","value":85.1,"profit":true},{"date":"2022-12-31","value":89.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 77.64% | 66.41% | 68.96% | 70.00% | 83.84% | [{"date":"2019-12-31","value":92.61,"profit":true},{"date":"2020-12-31","value":79.21,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":83.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 12.46B | 17.86B | 19.86B | 21.83B | 28.11B | [{"date":"2019-12-31","value":44.32,"profit":true},{"date":"2020-12-31","value":63.52,"profit":true},{"date":"2021-12-31","value":70.66,"profit":true},{"date":"2022-12-31","value":77.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | 12.98B | 476.00M | 17.92B | 18.12B | 17.43B | [{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":2.63,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.18,"profit":true}] |
Total Non-Operating Income/Expense | (6.07B) | 642.00M | (5.90B) | (5.34B) | (12.86B) | [{"date":"2019-12-31","value":-944.86,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-918.54,"profit":false},{"date":"2022-12-31","value":-831.31,"profit":false},{"date":"2023-12-31","value":-2002.96,"profit":false}] |
Pre-Tax Income | 8.43B | 3.40B | 12.99B | 13.48B | 6.25B | [{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}] |
Income Taxes | 544.00M | (1.22B) | 1.44B | 1.63B | 1.38B | [{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-75,"profit":false},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}] |
Income After Taxes | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}] |
Income From Continuous Operations | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 7.88B | 4.62B | 11.54B | 11.84B | 4.86B | [{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}] |
EPS (Diluted) | 8.94 | 10.51 | 12.68 | 13.87 | 11.11 | [{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
ABBV | |
---|---|
Cash Ratio | 0.44 |
Current Ratio | 0.94 |
Quick Ratio | 0.83 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ABBV | |
---|---|
ROA (LTM) | 7.71% |
ROE (LTM) | 56.24% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ABBV | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.95 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.05 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 18.59 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ABBV | |
---|---|
Trailing PE | 52.01 |
Forward PE | 14.58 |
P/S (TTM) | 5.29 |
P/B | 27.74 |
Price/FCF | 80 |
EV/R | 6.15 |
EV/Ebitda | 19.45 |
PEG | NM |
Ophthalmic Drugs Market Trends Overview 2024-2031: A new Report by Coherent Market Insights, titled "Ophthalmic Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031," offers a comprehensive analysis of the industry, which comprises insights on the Ophthalmic Drugs market
While active acquisition is perhaps the most common methodology of gaining wealth, it’s not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea. So, you need to find a way to have your money make money, which is where high-yield dividend stocks come into play. When participating in the equities space, it’s generally a good idea to have exposure to passive-income-providing enterprises. Your stable blue chips provide a frequent flow of income (typically on a quarterly basis). Space out your high-yield dividend stocks by their payment dates and you can potentially enjoy robust yields every month. This may allow you to pay your bills. Best of all, passive income is, well, passive. You don’t have to do anything to get the payout (so long as the company remains consistently profitable). With that in mind, below are high-yield dividend stocks to consider. PepsiCo (PEP) Source: FotograFFF / Shutterstock One of the world’s biggest beverage and snack product manufacturers, PepsiCo (NASDAQ: PEP ) makes a great case for high-yield dividend stocks.
DataM Intelligence has published a new research report on "Hidradenitis Suppurativa Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers.
At this writing, current inflation rate is 3% over the past 12 months. That’s the reading as of the end of June . So, in searching for high-yield dividend stocks beating inflation, I need to identify those with dividend yields above 3%. Fortunately, there are plenty of options in that range for investors. As always, it’s best to search within what is considered the healthy range of 2% to 6%. That’s a good rule of thumb, although there are exceptions to the rule. Consumers are fed up with inflation, although there are signs that it is continuing to abate. We are well above the target rate of 2%, driving investors and consumers to seek solutions. One solution is identifying and investing in stocks with dividends above the inflation rate. Doing so effectively cancels the negative effects of inflation to some degree. AbbVie (ABBV) Source: Piotr Swat / Shutterstock.com AbbVie (NYSE: ABBV ) is one of the better-known pharmaceutical stocks available to investors. It’s a stock well known to provide a strong dividend and is currently yielding 3.7%.
Rob Sechan, CEO of NewEdge Wealth, joins CNBC''s "Halftime Report" to discuss his latest moves. The Committee discuss the Healthcare sector.
AbbVie Inc (ABBV) share price today is $172.32
Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.
You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:
The 52-week high price of AbbVie Inc (ABBV) is $179.55. The 52-week low price of AbbVie Inc (ABBV) is $132.11.
The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 51.29
The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 27.74
The dividend yield of AbbVie Inc (ABBV) is 3.54%
The market capitalization of AbbVie Inc (ABBV) is $304.29B
The stock symbol (or ticker) of AbbVie Inc is ABBV